Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease

Area of Science:

• Hepatology
• Internal Medicine
• Gastroenterology

Background:

• Metabolic-associated fatty liver disease (MAFLD) is a recently proposed entity.
• Characteristics of patients with co-existing autoimmune hepatitis (AIH) and MAFLD are not well understood.
• Clarifying these characteristics is crucial for effective patient management.

Purpose of the Study:

• To evaluate the clinical characteristics of patients with autoimmune hepatitis (AIH) and co-existing metabolic-associated fatty liver disease (MAFLD).
• To compare patients with AIH and MAFLD against those with AIH alone.

Main Methods:

• Re-analysis of the 2018 Japanese Nationwide Survey of AIH.
• Inclusion of patients diagnosed with AIH between 2014 and 2017.
• Categorization of AIH patients based on the presence or absence of MAFLD for comparative analysis.

Main Results:

• Prevalence of MAFLD among AIH patients was 10.5% (45 out of 427 patients).
• AIH patients with MAFLD exhibited higher BMI, increased hypertension rates, milder initial liver enzyme/bilirubin elevation, and more advanced fibrosis.
• Post-treatment, AIH patients with MAFLD showed significantly higher hepatobiliary enzyme and total bilirubin levels compared to those without MAFLD.

Conclusions:

• AIH patients with MAFLD present distinct clinical and biochemical profiles compared to AIH patients without MAFLD.
• These findings contribute to a better understanding of the interplay between AIH and MAFLD.
• Further research into managing this specific patient cohort is warranted.